Evidence map›Paper›PMID 42205144›Full record

ArticleEClinicalMedicine2026

Population health outcomes in Qatar 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Abdulqadir J Nashwan, Hana J Abukhadijah, Mariam N Al-Mutawa, Ahmad A Abujaber, Ameena Jesaimani, Binny Thomas, Abdul Rouf Palli Valapila

Abstract read
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdulqadir J NashwanNursing & Midwifery Department, Hamad Medical Corporation, 3050, Doha, Qatar.
Hana J AbukhadijahClinical Trials Unit, Medical Care and Research Center, Hamad Medical Corporation, 3050, Doha, Qatar.
Mariam N Al-MutawaNursing & Midwifery Department, Hamad Medical Corporation, 3050, Doha, Qatar.
Ahmad A AbujaberNursing & Midwifery Department, Hamad Medical Corporation, 3050, Doha, Qatar.
Ameena JesaimaniCorporate Pharmacy Department, Hamad Medical Corporation, 3050, Doha, Qatar.
Binny ThomasCorporate Pharmacy Department, Hamad Medical Corporation, 3050, Doha, Qatar.
Abdul Rouf Palli ValapilaClinical Trials Unit, Medical Care and Research Center, Hamad Medical Corporation, 3050, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patterns of health and disease in Qatar have shifted substantially over the past three decades, reflecting demographic expansion, economic transition, and significant improvements in health system capacity. A comprehensive, up-to-date evaluation of disease burden is essential to guide priority-setting, resource allocation, and national health planning. However, no prior study has systematically assessed long-term trends in morbidity, mortality, and risk factors in Qatar using the most recent epidemiological data consistent with the Global Burden of Disease (GBD) Study framework. This study addresses this gap by providing a detailed analysis of population health outcomes in Qatar from 1990 to 2023. Methods: We conducted a secondary analysis of publicly available Global Burden of Disease (GBD) 2023 modelled estimates of mortality, prevalence, incidence, disability-adjusted life-years (DALYs), years of life lost (YLLs), and risk factor-attributable disease burden in Qatar. Data sources included vital registration records, hospital and registry datasets, survey data, and modelled estimates, as appropriate. Changes were examined across three major cause categories: non-communicable diseases (NCDs), communicable, maternal, neonatal, and nutritional (CMNN) diseases, and injuries-over four analytic periods (1990-2000, 2000-2015, 2015-2023, and 1990-2023). Uncertainty intervals (UIs) were derived from 250 posterior draws. The study followed GBD guidelines for reporting and estimation transparency. Findings: Qatar has achieved substantial progress in reducing the burden of CMNN diseases since 1990, driven by expanded immunisation coverage, improved maternal and neonatal care, and strengthened primary health services. However, the burden of NCDs has risen markedly and now accounts for the majority of mortality and DALYs. The leading contributors to NCD burden in 2023 were ischaemic heart disease, diabetes mellitus, cancer, chronic kidney disease, and neurological disorders. High body-mass index, high fasting plasma glucose, hypertension, dietary risks, and tobacco use were the predominant metabolic and behavioural risk factors. Road traffic injuries remained a leading cause of premature mortality, particularly among young men, reflecting Qatar's predominantly male working-age expatriate population and high rates of occupational and vehicular mobility. COVID-19 temporarily reversed declines in infectious disease burden during 2020-2021, although trends returned to levels consistent with the 2018 pre-pandemic trajectory by 2023. Interpretation: The epidemiological profile of Qatar is characterised by declining infectious disease burden and rising chronic disease and injury burden, shaped by demographic composition and lifestyle transitions. Addressing the growing impact of NCDs and injuries will require sustained preventive strategies, population-level risk factor reduction, strengthened primary care for chronic disease management, and coordinated multisectoral policy responses targeting diet, physical activity, road safety, and occupational health. These findings provide an evidence base to support national health planning and ongoing progress toward equitable and sustainable population health in Qatar. Funding: The publication of this study was funded by the Medical Research Center (MRC)at Hamad Medical Corporation (HMC), Doha, Qatar.

Indexed as

Causes of deathDALYsGBDGlobal burden of diseaseMortalityQatarRisk factors

Identifiers

PMID42205144
PMCPMC13208085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.